´Ý±â
TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢tkbd@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.


NEWS
 Á¦¸ñ : [°øÁö] 12/15 Mirus Webniar - Gene Therapy and Genome Editing Using Recombinant AAV Vectors
ÀÛ¼ºÀÏ : 2020.12.14
 ÀÛ¼ºÀÚ : ´ÙÄ«¶óÄÚ¸®¾Æ

Transfection Àü¹®±â¾÷ Mirus¿¡¼­ 12¿ù 15ÀÏ Webniar¸¦ ÁøÇàÇÕ´Ï´Ù.

 

When: 2020³â 12¿ù 15ÀÏ 11:00 AM EST

Topic:

  • Why AAV vectors are such commonly used gene transfer vehicle for in vivo gene therapy approaches
  • Current limitations using AAV vectors
  • Challenges moving from preclinical animal studies to humans

 

Register Now (¹«·áµî·Ï) ¡é¡é¡é

Gene Therapy and Genome Editing Using Recombinant AAV Vectors

 

Transfection Àü¹®°¡ Mirus¿¡¼­ ÁøÇàÇÏ´Â º» Webinar¿¡ ¸¹Àº °ü½É ºÎŹµå¸³´Ï´Ù.

 

** ÀüÀÓ»óÀ» À§ÇÑ AAV, Lentivirus ´ë·®»ý»ê¿¡´Â**

New TransIT-VirusGEN¢ç SELECT Transfection Reagent (Code MIR 6730) (Á¦Ç°ÆäÀÌÁö ¸µÅ©)

 

 

ÀÚ¼¼ÇÑ ¹®ÀÇ»çÇ×Àº °í°´Áö¿ø¼¾ÅÍ (02-2081-2510, support@takara.co.kr) ·Î ¿¬¶ô¹Ù¶ø´Ï´Ù.

°¨»çÇÕ´Ï´Ù.

 ¸ñ·ÏÀ¸·Î